Global Markets for Genetic Testing Until 2020 – Genetic Discovery Creates New Diagnostic Markets; Pharmacogenomics boosts growth

DUBLIN July 6, 2018 / PRNewswire / –

"The Global Market for Genetic Testing through Direct, Consumer, Prenatal, Predictive and Pharmacogenomic Testing, Including Price and Volume Tests with 2018 to 2020 Management Guides and Advisors "report was added to the offer of ResearchAndMarkets.com

Will All Newborns Get Whole Genomic Sequencing at Birth? What is the main interest that drives Direct to Consumer?

The report predicts the size of the market up to 2020. The report includes detailed breakdowns for 14 countries and 5 regions.

The role of genetics in health and disease is being understood. This new knowledge, combined with lower prices, is pushing the genetic testing industry to record record growth. New drugs may only work for people with some genetic background, and this too stimulates the genetic testing industry. The traditional market for genetic testing is growing in volume and growing in the scale of tests creating a new life for the industry.

Predictive diagnosis? Pharmacogenomic tests Direct to the consumer? Learn about technology in easy-to-understand terms that explain jargon. What are the problems? Find opportunities and pitfalls. Understand growth forecasts and market forecasts for the next five years.

Market Dynamics

Growth Factors

• Genetic Discovery Creates New Diagnostic Markets
• 19659010] Pharmacogenomics Boosts Growth
• Point-of-Care Testing Can Increase demand
• Fertility
• Direct to Consumer

Growth Limiting Factors

• Increased Competition Decreases Price
• Lower Costs
• Analysis Decreasing Growth
• Welfare Has a Disadvantage
• 19659015] Subjects dealt with

  1. Introduction and definition of the market
  1.1 Definition of genetic tests in this report
  1.2 The genomic revolution
  1.3 Definition of the market
  1.3.1 Volumes
  1.3.2 Price
  1.3.3 Market Income
  1.4 US Medical Market and Laboratory Tests – Perspective
  1.4.1 United States Health Insurance Expenses for Laboratory Tests

  2. Market Overview
  2.1 Market Participants Play Different Roles
  2.1.1 Supplier / Pharmaceutical
  2.1.2 Independent / Esoteric Independent Laboratory
  2.1.3 National / Regional Independent Laboratory
  2.1 .4 Independent Analytical Laboratory
  2.1.5 National / Regional Public Laboratory
  2.1.6 Hospital Laboratory
  2.1.7 Physicist Laboratory
  2.1.8 DTC Laboratory
  2.1.9 Independent Laboratory of genetic tests
  2.1 .10 Audit
  2.2 Genetic testing – Types, examples and discussion
  2.2.1 Pre-implantation diagnosis – An emerging market
  2.2.2 Prenatal diagnosis – New technologies create opportunities
  2.2. 3 Newborn screening
  2.2.2 Diagnostic tests
  2.2.3 Carrying tests
  2.2.6 Predictive and presymptomatic tests
  2.2.7 Pharmacogenomics
  2.2.8 Medico-legal tests
  ] 2.2.9 Parental Test
  2.2.10 Ancestral Test
  2.3 Structure of the Industry
  2.3.1 Ho Test Sharing of Spital
  2.3.2 Savings
  2.3.2.1 Hospital vs Central Laboratory
  2.3.3 Medical Laboratory Laboratory
  2.3.4 Physician and POCT
  2.4 Key Company Profiles
  2.4.1 Roche Molecular Diagnostics
  2.4.2 Illumina
  2.4.3 Grail
  2.4.4 Complete Genomics – BGI
  2.4.5 Qiagen
  2.4.6 GE Global Research
  ] 2.4.7 BGI Genomics Co. Ltd.
  2.4.8 Oxford Nanopore Technologies
  2.4.9 Genomic Health
  2.4.10 Pacific Biosciences
  2.4.11 Siemens Healthcare [19659023] 2.4.12 23 and me
  2.4.13 Ancestry.com
  2.4.14 Bio-Rad
  2.4.15 Thermo Fisher [19659023] 2.4.16 Genomics of Tissue
  ] 2.4.17 Centogen
  2.4.18 Gene Gene Gene
  2.4.19 Genetics of Veritas
  2.4.20 Dante Labs
  2.4.21 Guardiome.
  2.4.22 Safe Genetics
  2.4.23 Novogen
  2.4.24 Helix
  2.4.25 Genomics Personalized Health (GPH)
  2.4 .26 Sequencing.com
  2.4.27 Omega Bioservices
  2.4.28 ORIG3N
  2.4.29 Human Longevity, Inc.
  2.4.30 Invitae
  2.5 Market shares of the main players in genetics – Analysis

  3. Market Trends
  3.1 Growth Factors
  3.1.1 Genetic Discovery Creates New Diagnostic Markets
  3.1.2 The Aging Population is a Boon to Diagnostics
  3.1.3 Pharmacogenomics Boosts Growth
  3.1.4 Point 3.1.5 The practice of fertility
  3.1.6 Direct to the consumer
  3.2 Factors limiting growth
  3.2.1 Increased competition decreases the price
  3.2.2 Reduced costs
  3.2.3 Analysis of the use of tests hinders growth
  3.2.4 Well-being has a disadvantage
  3.3 Instrumentation and automation
  3.3.1 Key Market Instruments
  3.3.2 Bioinformatics Play a Role
  3.4 Development of Diagnostic Technology
  3.4.1 Sequencing the Next Generation Fueling a Revolution
  3.4.2 Impact of NGS on the tar 3.4.4 Diagnosis and Treatment of Pharmacogenomic Blur
  3.4.5 CGES Testing, A Brave New World
  3.4.6 3.4.4 Diagnosis and Treatment of Pharmacogenomic Blur
  3.4.5 CGES Testing, A Brave New World
  3.4.6 3.4.4 POCT / Interference Force of Self-Evaluation
  3.4.6 Biochips / Giant magnetoresistance-based test

  4. Genetic Testing Recent Developments
  4.1 Recent Developments – Importance and How to Use this Section
  4.1.1 Importance of these Developments
  4.1.2 How to Use this Section
  4.26 Myriad Genetics to Acquire Counsyl for $ 375M
  4.27 Rock Ink $ 2.4B Case to Acquire the Foundation Medicine
  4.28 Rapid Genome Sequencing Could Revolutionize Health Care
  4.2 The Future Goal of the United Kingdom is sequencing its entire genome
  4.3 Human Longevity Launches an Entire Genomic Product, MbadMutual Partnerships
  4.4 Influence of Sequential Whole Genome Growth
  4.5 The Rady and Edico Children's Genome Extends WGS Collaboration
  4.6 $ 1500 To Sequence Newborns In China
  4.8 Eurofins Acquiring Activity PerkinElmer NTD Lab Services
  4.9 GeneInsight Acquisition Stimulates Sunquest Genetic Software Platform
  4 .10 AstraZeneca Exploits Venter Gene Pioneer for a Huge Drug Scan
  4.11 The Cooper Women's Health Care Unit Acquires Genesis Genetics
  4.12 Research Validates Preimplantation Genetic Diagnosis of Aneuploidy (PGD-A)
  4.13 New Investments 4.14 Scientists Find Out new nanoparticles, nicknamed exomers, released by tumors
  4.16 New DNA tests detect 190 diseases in the genetic code of the newborn
  4.17 Cordlife, partner of PlumCare to offer genetic testing services in Asia
  4.18 A New Genetic Risk Score Could Guide Prostate Cancer Screening Decisions
  4.19 A Phone Driver enogenetics makes genetic counseling accessible
  The digital badistant OptraGURU is launching today at Optra Health
  4.21 PacBridge Capital Partners invests 12 million Canadian dollars in contextual genomics [19] 452214] 4.22 MDxHealth 2017 Revenues increase by 35% on prostate cancer tests
  4.23 From DNA to disease: A diagnosis made in less than a day
  4.24 A new tool uses CRISPR to discover genetic mutations
  -Marque IVD for the determination of leukemia
  4.89 Floragenex, Sedia Biosciences merge
  4.90 Myriad Genetics signs a definitive agreement for the acquisition of Assurex Health
  4.91 Genomics of Berry seeks to publish in China Via Reverse Merger
  4.92 Athletigen sees genetic testing as part of spo training rtif
  4.93 AncestryDNA sees huge growth in demand for genetic testing
  4.93 Phosphorus raises $ 10 million in Series A Funding to build a clinical genomics network
  4.94 Revenues of Neo-genomic Q1 jump on genetic test volume growth
  4.95 Nevada population health study to offer free genetic testing of 23andMe to the community
  4.96 Danaher to buy Cepheid in $ 4 billion case to develop in diagnosis
  4.97 Floragenex, fusion of Sedia Biosciences
  4.98 miRagen Therapeutics and signal genetics agree to merge
  4.99 Abbott seeks to exit Alere Deal
  4.100 Capnia, Essentialis to merge, focusing on the treatment of rare diseases
  4.101 Novartis concludes sale of Genoptix Lab business
  4.102 Konica Minolta to buy Ambry Genetics, treat up to $ 1 billion
  4.103 PerkinElmer launches full genome clinical sequencing Services
  4.104 The WGS and AI help clinicians to Developing Precision Oncology
  4.105 Dante Laboratories Associates with Amazon UK for Whole Genome Sequencing 349
  4.107 Genomics Launches Custom Wellness App for Sequencing. 4.108 CDC invests in WGS to help states respond to infectious disease threats
  4.109 Medica lll factory contamination likely source of M. chimaera infection in patients in several countries
  4.110 IBM Watson impresses in the badysis of brain tumors WGS
  4.111 OneOme, Genome. A partner to provide a genetic risk, PGx Service in Australia
  4.112 Salmonella outbreak control aids
  4.113 CombiMatrix in a merger agreement with a guest to be acquired for $ 33 million in ordinary shares Invitae

  5. Sizes of national markets – North America
  5.1 United States of America
  5.1.1 Prenatal and neonatal tests – Volumes, prices, revenues
  5.1.2 Predictive tests – Volumes, prices, revenues
  5.1.3 Pharmacogenomic trials – Volumes, prices, revenues
  5.1.4 Direct tests to consumers – Volumes, prices, revenues
  5.1.5 All genetic tests – Volumes, prices , income
  5.2 Canada
  5.2.1 Prenatal and neonatal tests – Volumes, prices, revenues
  5.2.2 Predictive tests – Volumes, prices, revenues
  5.2.3 Pharmacogenomic tests – Volumes, prices, revenues
  5.2.4 Direct tests to consumers – Volumes, prices, revenues
  5.2.5 All genetic tests – Volumes, prices, revenues

  6. Country Markets – Europe
  6.1 France
  6.1.1 Prenatal and Neonatal Trials – Volumes, Prices, Revenues
  6.1.2 Predictive Tests – Volumes, Prices, Revenues
  6.1. 3 Pharmacogenomic trials – Volumes, prices, revenues
  6.1.4 Direct tests to consumers – Volumes, prices, revenues
  6.1.5 All genetic tests – Volumes, prices, revenues
  6.2 Germany [19659050] 6.2.1 Prenatal and neonatal tests – Volumes, prices, revenues
  6.2.2 Predictive tests – Volumes, prices, revenues
  6.2.3 Pharmacogenomic tests – Volumes, prices, revenues
  6.2.4 Direct to Consumer Testing – Volumes, Prices, Revenues
  6.2.5 All Genetic Testing – Volumes, Prices, Revenues
  6.3 United Kingdom
  6.3.1 Prenatal and Neonatal Tests – Volumes, price, revenue
  6.3.2 Predictive tests – Volumes, prices, revenues
  6.3.3 Pharmacogenomic tests – Volumes, Prices, Revenues
  6.3.4 Direct consumer test – Volumes, prices, revenues
  6.3.5 All genetic tests – Volumes, prices, revenues
  6.4 Spain [19659049] 6.4.1 Prenatal and 6.4.2 Predictive tests – Volumes, prices, revenues
  6.4.3 Pharmacogenomic tests – Volumes, prices, revenues
  6.4.4 Direct tests to consumers – Volumes, prices, Income
  6.4.5 All genetic tests – Volumes, Prices, Revenues
  6.5 Italy
  6.5.1 Prenatal and neonatal tests – Volumes, Prices, Revenues
  6.5.2 Predictive tests – Volumes, prices, revenues
  6.5.3 Pharmacogenomic tests – Volumes, prices, revenues
  6.5.4 Direct tests to consumers – Volumes, prices, revenues
  6.5.5 All genetic tests – Volumes, prices, revenues
  6.6 Russia
  6.6.1 Prenatal and neonatal tests – Volumes, prices, revenues
  6.6.2 Predictive tests – Volumes, prices, revenues
  6.6.3 Pharmacogenomic tests – Volumes, prices, income
  6.6.4 Direct consumer testing – Volumes, prices, revenues
  6.6.5 TB Genetic Testing – Volumes, Prices, Revenues
  6.7 Rest of Europe and Former Soviet Union
  6.7.1 Prenatal and Neonatal Tests – Volumes, Prices, Revenues
  6.7.2 Tests Predictors – Volumes, Prices, Revenues
  6.7.3 Pharmacogenomic Testing – Volumes, Prices, Revenues
  6.7.4 Direct Testing to Consumers – Volumes, Prices, Revenues
  6.7.5 All Genetic Testing – Volumes , prices, revenues [19659006] 7. Country Markets – Asia Pacific
  7.1 China
  7.1.1 Prenatal and Neonatal Trials – Volumes, Prices, Revenues
  7.1.2 Predictive Tests – Volumes, Prices, Revenues
  7.1 .3 Pharmacogenomic Testing – Volumes, Prices, Revenue
  7.1.4 Direct Testing of Consumers – Volumes, Prices, Revenues
  7.1.5 All Genetic Testing – Volumes, Prices, Revenues
  7.2 Japan [19659050] 7.2.1 Prenatal and neonatal trials – Volumes, prices, revenues
  7.2.2 Predictive tests – Volumes, prices, revenues
  7.2.3 Pharmacogenomic tests – Volumes, prices, revenues
  7.2 .4 Direct to Consumer Tests – Volumes, Prices, Revenues
  7.2.5 All Genetic Testing – Volumes, Prices, Revenues
  7.3 South Korea
  7.3.1 Prenatal and Neonatal Testing – Volumes, prices, revenues
  7.3.2 Predictive tests – Volumes, prices, revenues
  7.3.3 Tests Pharmacogenomics – Volumes, Pr ices, Income
  7.3.4 Direct consumer testing – Volumes, prices, revenues
  7.3.5 All genetic tests – Volumes, prices, revenues
  7.4 India [19659049] 7.4.1 Prenatal and 7.4.2 Predictive tests – Volumes, prices, revenues
  5.1.3 Pharmacogenomic tests – Volumes, prices, revenues
  7.4.4 Direct consumer test – Volumes, prices, Income
  7.4.5 All genetic tests – Volumes, prices, revenues
  7.5 Australia
  7.5.1 Prenatal and neonatal tests – Volumes, prices, revenues
  7.5.2 Predictive tests – Volumes, price, revenue
  7.5.3 Pharmacogenomic Testing – Volumes, Prices, Revenues
  7.5.4 Direct Testing to Consumers – Volumes, Prices, Revenues
  7.5.5 All Genetic Testing – Volumes, Prices, Revenues
  7.6 Rest of Asia-Pacific
  7.6.1 Prenatal and neonatal tests – Volum , price, income
  7.6.2 Predictive tests – Volumes, prices, revenues
  7.6.3 Pharmacogenomic trials – Volumes, prices, revenues
  7.6.4 Direct tests for consumers – Volumes, prices, revenues
  7.6. 5 All genetic tests – Volumes, prices, revenues

  8. Country Markets – Latin America Africa & The Middle East
  8.1 Brazil
  8.1.1 Prenatal and Neonatal Testing – Volumes, Prices, Revenues
  8.1.2 Predictive trials – Volumes, prices, revenues
  8.1.3 Pharmacogenomic trials – Volumes, prices, revenues
  8.1.4 Direct consumer testing – Volumes, prices, revenues
  8.1.5 All genetic tests – Volumes, prices, revenues
  8.2 Mexico
  8.2.1 Prenatal and neonatal tests – Volumes, prices, revenues
  8.2.2 Predictive tests – Volumes, prices, revenues
  8.2 .3 Pharmacogenomic Testing – Volumes, Prices, Revenue
  8.2.4 Direct Testing for Consumers – Volumes, Prices, Revenue
  8.2.5 All Genetic Testing – Volumes, Prices, Revenues
  8.3 Remainder of ] Latin America
  8.3.1 Prenatal and neonatal tests – Volumes, prices, incomes
  8.3.2 Predictive tests – V olumes, prices, revenues
  8.3.3 Pharmacogenomic tests – Volumes, prices, revenues
  8.3.4 Direct tests to consumers – Volumes, prices, revenues
  8.3.5 All genetic tests – Volumes, prices, revenues
  8.4 Africa and Middle East
  8.4.1 Prenatal and neonatal tests – Volumes, prices, revenues
  8.4.2 Predictive Tests – Volumes, Prices, Revenues
  8.4.3 Pharmacogenomic Testing – Volumes, Prices, Revenues
  8.4.4 Direct Consumer Testing – Volumes, Prices, Revenues
  8.4.5 All Genetic Testing – Volumes, prices, revenues

  9. Global Market Summary
  9.1 World Market
  9.1.1 Prenatal and Neonatal Tests – Volumes, Prices, Revenues
  9.1.2 Predictive Tests – Volumes, Prices, Revenues
  9.1.3 Pharmacogenomic Testing – Volumes, Prices, Revenues
  9.1.4 Direct Consumer Testing – Volumes, Prices, Revenues
  9.1.5 All Genetic Testing – Volumes, Prices, Revenues

  10. The Future of Genetic Testing

  Appendices
  I. United States Health Care System: January 2016 Laboratory Fee Schedule – National Limit and Midpoint
  II Methodology
  II.1 Authors
  II.2 Sources

  For more information on this report visit https://www.researchandmarkets.com/research/x4l8fg/global_genetic?w=5

  Media Contact:

  Laura Wood Senior Director
  ] [email protected]

  For the opening hours of the EST, call + 1-917-300-0470
  For free call US / CAN + 1-800-526-8630
  For office hours GMT Call +353 -1-416-8900 [19659007] United States Fax: 646-607-1907
  Fax (out of the United States): + 353-1-481-1716

  See original content: http: //www.prnewswire .com / news-releases / global -genetic-test ing-markets-to-2020 — genetics-discovery-creates-new-diagnostic-markets-pharmacogenomics-grows-more-growth-300676911.html

  SOURCE Research and Markets